GUTS vs. NVRO, RCEL, ELMD, LAKE, INGN, BWAY, DRTS, PROF, TLSI, and SKIN
Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include Nevro (NVRO), AVITA Medical (RCEL), Electromed (ELMD), Lakeland Industries (LAKE), Inogen (INGN), BrainsWay (BWAY), Alpha Tau Medical (DRTS), Profound Medical (PROF), TriSalus Life Sciences (TLSI), and Beauty Health (SKIN). These companies are all part of the "medical equipment" industry.
Fractyl Health vs.
Fractyl Health (NASDAQ:GUTS) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
Nevro received 500 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 62.53% of users gave Nevro an outperform vote.
Nevro has a net margin of -16.54% compared to Fractyl Health's net margin of -64,849.48%. Fractyl Health's return on equity of 0.00% beat Nevro's return on equity.
Fractyl Health has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Fractyl Health has higher earnings, but lower revenue than Nevro. Nevro is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
95.5% of Nevro shares are owned by institutional investors. 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Fractyl Health currently has a consensus price target of $10.00, suggesting a potential upside of 809.09%. Nevro has a consensus price target of $6.43, suggesting a potential upside of 9.90%. Given Fractyl Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Fractyl Health is more favorable than Nevro.
In the previous week, Nevro had 4 more articles in the media than Fractyl Health. MarketBeat recorded 7 mentions for Nevro and 3 mentions for Fractyl Health. Nevro's average media sentiment score of 0.42 beat Fractyl Health's score of 0.00 indicating that Nevro is being referred to more favorably in the news media.
Summary
Nevro beats Fractyl Health on 9 of the 17 factors compared between the two stocks.
Get Fractyl Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fractyl Health Competitors List
Related Companies and Tools
This page (NASDAQ:GUTS) was last updated on 4/4/2025 by MarketBeat.com Staff
